Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
4,16 USD | 0,00% | -6,09% | -30,55% |
Omzet 2024 * | 395 mln. 370 mln. | Omzet 2025 * | 484 mln. 453 mln. | Marktkapitalisatie | 858 mln. 803 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -128 mln. -120 mln. | Nettowinst (verlies) 2025 * | -65 mln. -60,79 mln. | EV/omzet 2024 * | 2,76 x |
Nettoschuld 2024 * | 234 mln. 219 mln. | Nettoschuld 2025 * | 259 mln. 242 mln. | EV/omzet 2025 * | 2,31 x |
K/w-verhouding 2024 * |
-6,6
x | K/w-verhouding 2025 * |
-12
x | Werknemers | 536 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 96,83% |
Recentste transcriptie over BioCryst Pharmaceuticals, Inc.
1 week | -6,09% | ||
Lopende maand | -18,11% | ||
1 maand | -16,97% | ||
3 maanden | -23,53% | ||
6 maanden | -23,81% | ||
Lopend jaar | -30,55% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jon Stonehouse
CEO | Chief Executive Officer | 63 | 01-01-07 |
Anthony Doyle
DFI | Director of Finance/CFO | 44 | 02-04-20 |
Ryan Arnold
CTO | Chief Tech/Sci/R&D Officer | - | 01-03-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Alan Levin
BRD | Director/Board Member | 62 | 27-02-20 |
Jon Stonehouse
CEO | Chief Executive Officer | 63 | 01-01-07 |
Director/Board Member | 60 | 26-07-21 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.23% | 0 M€ | 0,00% | - | |
0.20% | 0 M€ | 0,00% | - | |
0.18% | 1 026 M€ | +6,95% | - | |
0.13% | 509 M€ | -.--% |
Datum | Koers | Variatie | Volume |
---|---|---|---|
26-04-24 | 4,16 | 0,00% | 2 310 948 |
25-04-24 | 4,16 | -1,19% | 2 735 562 |
24-04-24 | 4,21 | -3,88% | 4 409 981 |
23-04-24 | 4,38 | -0,68% | 4 236 664 |
22-04-24 | 4,41 | -0,45% | 2 557 483 |
uitgestelde koers Nasdaq, 26 april 2024 om 22:00 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-30,55% | 858 mln. | |
-2,31% | 103 mld. | |
+0,56% | 95,28 mld. | |
+1,69% | 22,15 mld. | |
-17,37% | 21,02 mld. | |
-9,30% | 18,15 mld. | |
-41,01% | 16,74 mld. | |
-14,85% | 16,05 mld. | |
+3,21% | 13,68 mld. | |
+33,54% | 12,17 mld. |